Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are highly heterogeneous myeloid diseases, characterized by frequent genetic/chromosomal aberrations. Olaparib is a potent, orally bioavailable poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with acceptable toxicity profile, designed as targeted therapy for DNA repai...

Full description

Bibliographic Details
Main Authors: Isabella Faraoni, Maria Irno Consalvo, Francesca Aloisio, Emiliano Fabiani, Manuela Giansanti, Francesca Di Cristino, Giulia Falconi, Lucio Tentori, Ambra Di Veroli, Paola Curzi, Luca Maurillo, Pasquale Niscola, Francesco Lo-Coco, Grazia Graziani, Maria Teresa Voso
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Cancers
Subjects:
MDS
PARP inhibitors
olaparib
hematopoietic differentiation
PARP1
AML
Online Access:https://www.mdpi.com/2072-6694/11/9/1373

Internet

https://www.mdpi.com/2072-6694/11/9/1373

Similar Items